Immunomedics Revenue and Competitors

Claim your profile

Location

$30M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Immunomedics's estimated annual revenue is currently $34.6M per year.(i)
  • Immunomedics received $125.0M in venture funding in May 2017.
  • Immunomedics's estimated revenue per employee is $187,853
  • Immunomedics's total funding is $30M.

Employee Data

  • Immunomedics has 184 Employees.(i)
  • Immunomedics grew their employee count by -19% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$10.9M70-3%N/AN/A
#2
$12.7M8215%N/AN/A
#3
$100.9M46517%N/AN/A
#4
$14.7M10418%$206.4MN/A
#5
$492.2M175212%$568MN/A
#6
$1.7M2729%N/AN/A
#7
$5M78-8%N/AN/A
#8
$3.5M35-8%$33.5MN/A
#9
$2M1318%N/AN/A
#10
$40.5M2615%N/AN/A

Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer and other serious diseases. Immunomedics corporate objective is to become a fully-integrated biopharmaceutical company and a leader in the field of antibody-drug conjugates.

keywords:Biotechnology,Cleantech,Healthcare,Medical Diagnostics,Pharmaceuticals,Wind Power

$30M

Total Funding

184

Number of Employees

$34.6M

Revenue (est)

-19%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Immunomedics News

2022-04-20 - Gilead Takes $2.7 Billion Writedown; Covid Drug Tops ...

Gilead raised eyebrows in 2020 when it agreed to buy Immunomedics for about $21 billion, a substantial premium for a company that was...

2022-04-13 - Gilead's Immunomedics floats $4M to put ASCO data fiasco to ...

Under a proposed settlement, Gilead Sciences' Immunomedics would shell out $4 million to resolve a lawsuit alleging it violated securities laws...

2022-04-06 - Immunomedics Investors Seek First Nod for $4 Million ...

Immunomedics Inc. investors who say the company misled them about cancer drug data presentations asked a federal judge in New Jersey for...

2019-09-12 - Immunomedics (IMMU) Looks Good: Stock Adds 6.1% in ...

Immunomedics, Inc. IMMU was a big mover last session, as the company saw its shares rise more than 6% on the day. The move came on solid ...

2019-09-12 - Immunomedics to Host Investor Event and Webcast on ...

12, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$60.5M334-3%N/A
#2
$118.7M4521%N/A
#3
$123.4M4913%N/A
#4
$596.5M1732N/AN/A
#5
$34640M125928-6%$11.4M

Immunomedics Funding

DateAmountRoundLead InvestorsReference
2004-01-15$10.0MnotesArticle
2005-04-28$36.7MUndisclosedMultipleArticle
2014-05-05$30.2MUndisclosedArticle
2015-02-09$96.4MUndisclosedGoldman, Sachs & Co.Article
2017-05-08$125.0MUndisclosedArticle